Journal Article

Excretion of MBDB and BDB in Urine, Saliva, and Sweat Following Single Oral Administration

Pascal Kintz

in Journal of Analytical Toxicology

Volume 21, issue 7, pages 570-575
Published in print November 1997 | ISSN: 0146-4760
Published online November 1997 | e-ISSN: 1945-2403 | DOI: http://dx.doi.org/10.1093/jat/21.7.570
Excretion of MBDB and BDB in Urine, Saliva, and Sweat Following Single Oral Administration

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)

GO

Show Summary Details

Preview

A procedure based on gas chromatography—mass spectrometry (GC-MS) for the simultaneous identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) and its desmethylated metabolite 3,4-(methylenedioxyphenyl)-2-butanamine (BDB) in urine, saliva, and sweat specimens is presented. For urine and saliva, the method involved the alkaline extraction of a 1-mL specimen (MDEA-d5 internal standard) into ethyl acetate followed by derivatization with heptafluorobutyric anhydride. Sweat specimens, which were collected by a sweat patch, were tested after methanolic elution. The procedure was used to study the excretion of MBDB and BDB in urine, saliva, and sweat after single oral administration of 100 mg of MBDB to one subject. Urine tested positive for 36 h with a peak concentration at 4 h. Immunoassays were positive for 24 and 4 h using FPIA and EMIT, respectively. Peak saliva concentration was observed at 2 h. MBDB and BDB were detected in saliva during the first 17 h. Finally, both compounds were excreted into sweat with a constant increase in concentration during the first 36 h followed by a decrease for the remaining time. In all the biological specimens that were tested, MBDB was present in higher concentrations than its metabolite.

Journal Article.  0 words. 

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.